Stock Events

Nuvectis Pharma 

$6.9
6
+$0.28+4.23% Today

Statistics

Day High
6.93
Day Low
-
52W High
15.5
52W Low
5.85
Volume
20,102
Avg. Volume
99,743
Mkt Cap
126.66M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

7MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.48
-0.32
-0.16
0
Expected EPS
-0.4
Actual EPS
-0.25

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVCT. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck &
MRK
Mkt Cap318.55B
Merck & Co., Inc. is a global healthcare company that develops medications in oncology, making it a direct competitor in the cancer treatment market where Nuvectis Pharma operates.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol-Myers Squibb is involved in the discovery, development, and delivery of cancer therapies, competing directly with Nuvectis Pharma in the oncology sector.
Pfizer
PFE
Mkt Cap169.83B
Pfizer Inc. has a broad portfolio of oncology drugs and invests heavily in cancer research, positioning it as a competitor to Nuvectis Pharma in the development of cancer treatments.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca PLC focuses on the development of new cancer drugs, including targeted therapies, competing with Nuvectis Pharma in the oncology pharmaceuticals market.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, Inc. is known for its innovative therapies in oncology, directly competing with Nuvectis Pharma in the cancer treatment space.
AMGEN
AMGN
Mkt Cap177.72B
Amgen Inc. has a strong presence in the oncology market with a focus on developing novel cancer treatments, making it a competitor to Nuvectis Pharma.
Rogers
ROG
Mkt Cap2.34B
Roche Holding AG is a major player in oncology, with a wide range of cancer drugs and therapies that compete with Nuvectis Pharma's offerings.
Novartis
NVS
Mkt Cap232.42B
Novartis AG is heavily involved in oncology research and drug development, offering a broad portfolio of cancer treatments that compete with Nuvectis Pharma.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals, Inc. is engaged in the development of cancer treatments, including immunotherapies, which positions it as a competitor to Nuvectis Pharma.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly and Company has a growing oncology division focused on developing innovative cancer treatments, competing with Nuvectis Pharma in the pharmaceuticals market.

Analyst Ratings

21$Average Price Target
The highest estimate is $21.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Show more...
CEO
Employees
13
Country
US
ISIN
US67080T1088

Listings

XNAS
US
NVCT